Vanguard Group Inc. Sells 184,364 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR)

Vanguard Group Inc. reduced its holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,666,854 shares of the company's stock after selling 184,364 shares during the quarter. Vanguard Group Inc. owned approximately 5.53% of Atea Pharmaceuticals worth $15,634,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. Intech Investment Management LLC boosted its holdings in shares of Atea Pharmaceuticals by 236.0% in the 4th quarter. Intech Investment Management LLC now owns 35,989 shares of the company's stock worth $121,000 after acquiring an additional 25,278 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Atea Pharmaceuticals by 72.9% during the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 76,352 shares of the company's stock worth $256,000 after buying an additional 32,195 shares in the last quarter. HighTower Advisors LLC acquired a new position in Atea Pharmaceuticals during the 4th quarter worth $168,000. CM Management LLC lifted its holdings in Atea Pharmaceuticals by 11.1% during the 4th quarter. CM Management LLC now owns 300,000 shares of the company's stock worth $1,005,000 after buying an additional 30,000 shares in the last quarter. Finally, BML Capital Management LLC lifted its holdings in Atea Pharmaceuticals by 14.4% during the 4th quarter. BML Capital Management LLC now owns 7,608,312 shares of the company's stock worth $25,488,000 after buying an additional 958,312 shares in the last quarter. 86.67% of the stock is owned by institutional investors and hedge funds.

Atea Pharmaceuticals Price Performance

Shares of Atea Pharmaceuticals stock traded up $0.03 on Wednesday, hitting $2.90. 58,901 shares of the company's stock traded hands, compared to its average volume of 289,271. The firm's 50-day moving average price is $2.99 and its two-hundred day moving average price is $3.17. The stock has a market capitalization of $248.02 million, a PE ratio of -1.40 and a beta of 0.17. Atea Pharmaceuticals, Inc. has a one year low of $2.60 and a one year high of $4.15.

Atea Pharmaceuticals (NASDAQ:AVIR - Get Free Report) last issued its earnings results on Thursday, March 6th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). On average, analysts forecast that Atea Pharmaceuticals, Inc. will post -2.01 earnings per share for the current fiscal year.

Analyst Ratings Changes

AVIR has been the topic of several research reports. William Blair reaffirmed an "outperform" rating on shares of Atea Pharmaceuticals in a report on Friday, March 7th. Morgan Stanley reduced their price objective on Atea Pharmaceuticals from $6.20 to $6.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.